• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Medical devices
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
ISPOR 2025: Trends in the prescribing and dispensing of GLP-1 anti-obesity medications among adults with cardiovascular disease

ISPOR 2025: Trends in the prescribing and dispensing of GLP-1 anti-obesity medications among adults with cardiovascular disease

by Truveta Research | May 14, 2025 | Research, Research Insights

Authors: Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Karthik Murugiah, MBBS, MHS ⊕Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven,...
ISPOR 2025: Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation 

ISPOR 2025: Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation 

by Truveta Research | May 14, 2025 | Research, Research Insights

Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD, PhD ⊕Truveta, Inc, Bellevue, WA Side effects were the most common...
ISPOR 2025: Characteristics and adherence of patients initiating injectable cabotegravir for HIV treatment or prevention 

ISPOR 2025: Characteristics and adherence of patients initiating injectable cabotegravir for HIV treatment or prevention 

by Truveta Research | May 14, 2025 | Research, Research Insights

Authors: Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD, PhD ⊕Truveta, Inc, Bellevue, WA Moderate adherence was observed for...
Women’s health: Pain medication remains rare for women receiving IUDs

Women’s health: Pain medication remains rare for women receiving IUDs

by Truveta Research | May 6, 2025 | Research, Research Insights

Although a majority of women report intrauterine device (IUD) insertion to be moderately to severely painful, so far in 2025, only 1 in 20 women received pain medication on the day of IUD insertion. The use of pain medication during IUD insertions more than doubled...
GLP-1 RA prescription trends: January 2018 – March 2025

GLP-1 RA prescription trends: January 2018 – March 2025

by Truveta Research | Apr 18, 2025 | Research, Research Insights

Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in March 2025 increased relative to December 2024 (+12.96%). Anti-diabetic medication (ADM) prescribing increased from December 2024 to January 2025, then remained relatively stable until March...
Study exploring syphilis infections among US adults published in American Journal of Preventative Medicine

Study exploring syphilis infections among US adults published in American Journal of Preventative Medicine

by Truveta staff | Apr 15, 2025 | Research, Research Insights

Truveta Research explored the monthly trends in the incidence of syphilis among US adults from January 2017 and October 2024. During the early months of the COVID-19 pandemic, the rate of syphilis incidence (e.g., new infection) increased significantly, reaching a...
« Older Entries
Next Entries »

Share this


Recent posts

  • Completing the evidence picture with linked EHR and closed claims data
  • Truveta recognized on national and Seattle LinkedIn Top Startup 2025 lists
  • AI and imaging open new avenues for studying body composition at scale

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.